CPHI Webinar: Early multi-functional approach is the best way to incorporate patient centricity into drug formulations
The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts
Designing effective patient-centric dosage forms needs to be underpinned by a practical multi-functional view which considers all the angles, according to a panel of experts speaking at a recent CPHI Webinar, available here on-demand.
In the Webinar Defining and Designing Patient-Centric Dosage Forms sponsored by SPI Pharma and chaired by Leanne West, Principal Research Scientist & Chief Engineer of Paediatric Technologies, Georgia Tech, the implications of designing drugs that tick all the boxes for patient centricity were discussed both from a commercial and academic perspective.
Dr Graeme Macleod, Global Research & Development Manager, SPI Pharma said it was important to take a multi-functional view on what is meant by patient centricity: “What does your target patient group look like, what is the disease, is the disease chronic or acute, where is the patient actually receiving the medicine, and are they in a particular group where it’s difficult to take the medication?”
He added that from a pharmaceutical development point of view, it was essential to get as much information as early in the development process as possible and not lose sight of certain commercial considerations such as ascertaining what technologies are available inhouse and the cost of development.
“From a formulation perspective, you’ve really got to think about not only designing the right dosage form, but also about what you can achieve practically,” he said. “In general, it’s about having a dose form that is safe and efficacious and trying to make it designed to be as patient centric as possible within the certain limitations we have.”
Nielsen Hobbs, Executive Editor, Policy and Regulation, Pink Sheet said the more formulation developers hold discussions with patients and take a “blue sky approach” to what is possible, “the easier their development could end up being.”
Hannah Batchelor, Professor, Strathclyde Institute of Pharmacy and Biomedical Sciences said patient centricity should be considered as early as possible in the drug development process.
She gave the example of a project for an oral product for rheumatoid arthritis in which developers did look from the very beginning at issues such as the size and shape of the tablet for easier handling and grip as patients may have dexterity issues.
“It is looked at relatively early; in development pipeline terms, it’s probably just prior to Phase I is where I’ve seen patient centricity considered previously,” she added.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance